Search - tctmd.com

Displaying 261 - 280 of 397

Sort: Relevancy | Date

News Daily News

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

L.A. McKeown

June 17, 2014

News Daily News

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

L.A. McKeown

June 17, 2014

News Daily News

Study Highlights Disparity Between Pre-, Postmarket Study Outcomes for DES

Caitlin E. Cox

June 13, 2014

News Daily News

Nationwide Registry Shows Trends in DES Use Over a Decade

June 02, 2014

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

News Conference News EuroPCR 2014

EuroPCR Features PAD Therapies in Early Development and Real-World Use

Caitlin E. Cox

May 21, 2014

News Conference News EuroPCR 2014

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Caitlin E. Cox

May 21, 2014

News Conference News EuroPCR 2014

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

Caitlin E. Cox

May 20, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

News Daily News

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

April 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

News Daily News

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Caitlin E. Cox

March 13, 2014

News Daily News

Los Balones liberadores de Fármacos Reducen la Reestenosis y la RLD en Pacientes Diabéticos con ICE

Yael L. Maxwell

February 26, 2014

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

News Daily News

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Jason Kahn

February 20, 2014

News Daily News

Stent Malapposition Frequent, But Without Clinical Consequences

Jason Kahn

January 27, 2014

News Daily News

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

January 01, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Advertisement

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Study Highlights Disparity Between Pre-, Postmarket Study Outcomes for DES

Nationwide Registry Shows Trends in DES Use Over a Decade

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

EuroPCR Features PAD Therapies in Early Development and Real-World Use

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Los Balones liberadores de Fármacos Reducen la Reestenosis y la RLD en Pacientes Diabéticos con ICE

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Stent Malapposition Frequent, But Without Clinical Consequences

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content